Anna Cereseto

Anna Cereseto is Full Professor at the University of Trento where she serves as Deputy Director of the Department CIBIO. She started her scientific career as post-doc at the National Cancer Institute, NIH in Bethesda, and then moved to Cornell University (NY) and Mount Sinai School of Medicine (NY) as Instructor. She moved back to Italy as Associate Professor of Molecular Biology at Scuola Normale Superiore in Pisa before moving to her current position at the University of Trento. She is leading a research group that gave major contribution in advancing genome editing technologies based CRISPR-Cas systems and proved their efficacy in reversing genetic defects causing one of the most frequent genetic disease, cystic fibrosis. Her research is supported by the European Community (Horizon 2020) and by the US and Italian Cystic Fibrosis Foundations (FFC and CFF). In 2019 she co-founded a start-up, Alia Therapeutics, working on genome editing treatments where she is currently chief scientific officer (CSO).